


**AMENDMENTS TO THE CLAIMS**

The following is a complete, marked up listing of revised claims with a status identifier in parentheses, underlined text indicating insertions, and strikethrough and/or double brackets indicating deletions.

Listing of the Claims

1. (CURRENTLY AMENDED) A compound of the following ~~general~~ formula (I):



(I)

wherein

R<sub>2</sub> designates hydrogen, Me, Et, CHO, CN, OH, OMe, COR<sub>9</sub>, COOR<sub>9</sub>, CONHR<sub>9</sub> or CSNHR<sub>9</sub>, whereby R<sub>9</sub> denotes (C<sub>1</sub>-C<sub>4</sub>) alkyl;

R<sub>5</sub> designates hydrogen, (C<sub>1</sub>-C<sub>4</sub>) alkyl, OH, (C<sub>1</sub>-C<sub>4</sub>) alkoxy, OCF<sub>3</sub>, trifluoromethyl or halogen;

R<sub>6</sub> designates Me, (C<sub>1</sub>-C<sub>4</sub>) alkoxy, OCF<sub>3</sub>, SMe or SEt;

n is 1 or 2;

R<sub>3</sub>' ~~an~~ and R<sub>5</sub>' each independently designate OH, Me, Et, OMe, OCF<sub>3</sub>, trifluoromethyl or halogen;

U designates N or CR<sub>2</sub>', whereby R<sub>2</sub>' denotes hydrogen, (C<sub>1</sub>-C<sub>4</sub>) alkyl, (C<sub>1</sub>-C<sub>4</sub>) alkoxy, trifluoromethyl or halogen;

V designates N or CR<sub>4</sub>', whereby R<sub>4</sub>' denotes hydrogen, (C<sub>1</sub>-C<sub>6</sub>) alkoxy, (C<sub>1</sub>-C<sub>6</sub>) alkyl, OH, trifluoromethyl or halogen;

W designates N or CR<sub>6</sub>', whereby R<sub>6</sub>' denotes hydrogen, (C<sub>1</sub>-C<sub>4</sub>) alkyl, (C<sub>1</sub>-C<sub>4</sub>) alkoxy, trifluoromethyl or halogen; ~~and~~ or pharmaceutically acceptable ~~salts~~ salt thereof.

2. (PREVIOUSLY PRESENTED) A compound according to claim 1, wherein R<sub>2</sub> designates Me, OH, CN, CHO, COR<sub>9</sub> or COOR<sub>9</sub>.

3. (PREVIOUSLY PRESENTED) A compound according to claim 1, wherein R<sub>2</sub> designates Me, CN, CHO or COMe.

4. (PREVIOUSLY PRESENTED) A compound according to claim 1, wherein R<sub>5</sub> designates hydrogen, Me, OMe or halogen.

5. (PREVIOUSLY PRESENTED) A compound according to claim 1, wherein R<sub>6</sub> designates OMe or OEt.

6. (CURRENTLY AMENDED) A compound according to claim 1, wherein R<sub>5</sub> designates hydrogen or OMe, ~~preferably hydrogen~~; and R<sub>6</sub> designates OMe.
7. (PREVIOUSLY PRESENTED) A compound according to claim 1, wherein R<sub>3</sub>' and R<sub>5</sub>' each independently designate chloro, bromo, Me or OMe.
8. (PREVIOUSLY PRESENTED) A compound according to claim 1, wherein R<sub>3</sub>' and R<sub>5</sub>' are identical; or R<sub>3</sub>' designates chloro or bromo, and R<sub>5</sub>' designates OMe.
9. (PREVIOUSLY PRESENTED) A compound according to claim 7, wherein R<sub>3</sub>' and R<sub>5</sub>' designate both chloro or both bromo.
10. (PREVIOUSLY PRESENTED) A compound according to claim 1, wherein U and W designate CH and V designates CR<sub>4</sub>'.
11. (PREVIOUSLY PRESENTED) A compound according to claim 10, wherein R<sub>4</sub>' designates hydrogen, chloro, bromo, Me or OMe.
12. (PREVIOUSLY PRESENTED) A compound according to claim 10, wherein R<sub>3</sub>', R<sub>4</sub>' and R<sub>5</sub>' designate OMe; or R<sub>3</sub>' designates chloro and R<sub>4</sub>' and R<sub>5</sub>' designate OMe; or R<sub>4</sub>' designates hydrogen and R<sub>3</sub>' and R<sub>5</sub>' designate both chloro or both bromo.

13. (CURRENTLY AMENDED) A-The compound according to claim 1, wherein the compound is one selected from the group consisting of, ~~which is~~ 1-(3,5-dichlorophenyl)-2-formyl-6-methoxy-1,2,3,4-tetrahydroisoquinoline, 1-(3,5-dichlorophenyl)-2-acetyl-6-methoxy-1,2,3,4-tetrahydroisoquinoline, 1-(3,5-dichlorophenyl)-2-cyano-6-methoxy-1,2,3,4-tetrahydroisoquinoline, 1-(3,5-dibromophenyl)-2-formyl-6-methoxy-1,2,3,4-tetrahydroisoquinoline, 1-(3,5-dibromophenyl)-2-acetyl-6-methoxy-1,2,3,4-tetrahydroisoquinoline, 1-(3,5-dibromophenyl)-2-cyano-6-methoxy-1,2,3,4-tetrahydroisoquinoline, 1-(3,5-dimethoxyphenyl)-2-formyl-6-methoxy-1,2,3,4-tetrahydroisoquinoline, 1-(3,5-dimethoxyphenyl)-2-acetyl-6-methoxy-1,2,3,4-tetrahydroisoquinoline, 1-(3,5-dimethoxyphenyl)-2-cyano-6-methoxy-1,2,3,4-tetrahydroisoquinoline, 1-(3,4,5-trimethoxyphenyl)-2-formyl-6-methoxy-1,2,3,4-tetrahydroisoquinoline, 1-(3,4,5-trimethoxyphenyl)-2-acetyl-6-methoxy-1,2,3,4-tetrahydroisoquinoline, 1-(3,4,5-trimethoxyphenyl)-2-cyano-6-methoxy-1,2,3,4-tetrahydroisoquinoline, 1-(3-chloro-4,5-dimethoxyphenyl)-2-formyl-6-methoxy-1,2,3,4-tetrahydroisoquinoline, 1-(3-chloro-4,5-dimethoxyphenyl)-2-acetyl-6-methoxy-1,2,3,4-tetrahydroisoquinoline 1-(3-chloro-4,5-dimethoxyphenyl)-2-cyano-6-methoxy-1,2,3,4-tetrahydroisoquinoline, 1-(3,5-dichlorophenyl)-2-formyl-6-methoxy-1,2,3,4-tetrahydroisoquinoline, 1-(3,5-dichlorophenyl)-2-acetyl-6-methoxy-1,2,3,4-tetrahydroisoquinoline, 1-(3,5-dichlorophenyl)-2-cyano-6-methoxy-1,2,3,4-tetrahydroisoquinoline, 1-(3,5-dibromophenyl)-2-formyl-6-methoxy-1,2,3,4-tetrahydroisoquinoline, 1-(3,5-dibromophenyl)-2-acetyl-6-

ethoxy-1,2,3,4-tetrahydroisoquinoline, 1-(3,5-dibromophenyl)-2-cyano-6-ethoxy-1,2,3,4-tetrahydroisoquinoline, 1-(3,5-dimethoxyphenyl)-2-formyl-6-ethoxy-1,2,3,4-tetrahydroisoquinoline, 1-(3,5-dimethoxyphenyl)-2-acetyl-6-ethoxy-1,2,3,4-tetrahydroisoquinoline, 1-(3,5-dimethoxyphenyl)-2-cyano-6-ethoxy-1,2,3,4-tetrahydroisoquinoline, 1-(3,4,5-trimethoxyphenyl)-2-formyl-6-ethoxy-1,2,3,4-tetrahydroisoquinoline, 1-(3,4,5-trimethoxyphenyl)-2-acetyl-6-ethoxy-1,2,3,4-tetrahydroisoquinoline, 1-(3,4,5-trimethoxyphenyl)-2-cyano-6-ethoxy-1,2,3,4-tetrahydroisoquinoline, 1-(3-chloro-4,5-dimethoxyphenyl)-2-formyl-6-ethoxy-1,2,3,4-tetrahydroisoquinoline, 1-(3-chloro-4,5-dimethoxyphenyl)-2-acetyl-6-ethoxy-1,2,3,4-tetrahydroisoquinoline or 1-(3-chloro-4,5-dimethoxyphenyl)-2-cyano-6-ethoxy-1,2,3,4-tetrahydroisoquinoline, 1-(3,5-dichlorophenyl)-2-formyl-5,6-dimethoxy-1,2,3,4-tetrahydroisoquinoline, 1-(3,5-dichlorophenyl)-2-acetyl-5,6-dimethoxy-1,2,3,4-tetrahydroisoquinoline, 1-(3,5-dichlorophenyl)-2-cyano-5,6-dimethoxy-1,2,3,4-tetrahydroisoquinoline, 1-(3,5-dibromophenyl)-2-formyl-5,6-dimethoxy-1,2,3,4-tetrahydroisoquinoline, 1-(3,5-dibromophenyl)-2-acetyl-5,6-dimethoxy-1,2,3,4-tetrahydroisoquinoline, 1-(3,5-dibromophenyl)-2-cyano-5,6-dimethoxy-1,2,3,4-tetrahydroisoquinoline, 1-(3,5-dimethoxyphenyl)-2-formyl-5,6-dimethoxy-1,2,3,4-tetrahydroisoquinoline, 1-(3,5-dimethoxyphenyl)-2-acetyl-5,6-dimethoxy-1,2,3,4-tetrahydroisoquinoline, 1-(3,5-dimethoxyphenyl)-2-cyano-5,6-dimethoxy-1,2,3,4-tetrahydroisoquinoline, 1-(3,4,5-trimethoxyphenyl)-2-formyl-5,6-dimethoxy-1,2,3,4-tetrahydroisoquinoline, 1-(3,4,5-trimethoxyphenyl)-2-acetyl-5,6-dimethoxy-1,2,3,4-tetrahydroisoquinoline, 1-(3,4,5-trimethoxyphenyl)-2-cyano-5,6-dimethoxy-1,2,3,4-tetrahydroisoquinoline,

trimethoxyphenyl)-2-acetyl-5,6-dimethoxy-1,2,3,4-tetrahydroisoquinoline, 1-(3,4,5-trimethoxyphenyl)-2-cyano-5,6-dimethoxy-1,2,3,4-tetrahydroisoquinoline 1-(3-chloro-4,5-dimethoxyphenyl)-2-formyl-5,6-dimethoxy-1,2,3,4-tetrahydroisoquinoline, 1-(3-chloro-4,5-dimethoxyphenyl)-2-acetyl-5,6-dimethoxy-1,2,3,4-tetrahydroisoquinoline or 1-(3-chloro-4,5-dimethoxyphenyl)-2-cyano-5,6-dimethoxy-1,2,3,4-tetrahydroisoquinoline, ~~or a~~ and pharmaceutically acceptable ~~salt~~ salts thereof.

14. (PREVIOUSLY PRESENTED) A compound according to claim 1, which is the (R) - or (S)-enantiomer.

15. (CURRENTLY AMENDED) A medicament, comprising the compound as ~~defined in~~ according to claim 1, ~~for use as a medicament.~~

16. (CURRENTLY AMENDED) ~~Use of a compound as defined in claim 1, for the preparation of~~ A method of preparing a medicament for the prophylaxis or treatment of a disease in which down-regulation or inhibition of the expression or function of the IGF-1 receptor is beneficial, comprising utilizing the compound according to claim 1.

17. (CURRENTLY AMENDED) The ~~use method~~ according to claim 16, wherein the disease is selected from cell proliferate diseases ~~such as~~including cancer, atherosclerosis, restenosis, inflammatory diseases ~~such as~~including psoriasis, and autoimmune diseases ~~such as~~including rheumatoid arthritis, and transplant rejection.

18. (CURRENTLY AMENDED) A method of treatment or prophylaxis of a disease leukemia, breast cancer, melanoma cancer or prostate cancer in which down-regulation or inhibition of the expression or function of the IGF-1 receptor is beneficial, in a subject in need of such treatment or prophylaxis, comprising administering to said subject an amount of ~~a~~the compound of formula (I) ~~as defined in~~according to claim 1 in an amount which is effective in down-regulating or inhibiting the expression or function of the IGF-1 receptor.

19. (CANCELLED)

20. (CURRENTLY AMENDED) A pharmaceutical composition, comprising: a ~~the~~ compound of formula (I), or ~~a~~the pharmaceutically acceptable salt thereof ~~as defined in~~according to claim 1; and a pharmaceutically acceptable adjuvant, diluent or carrier.

21. (CURRENTLY AMENDED) ~~Articles~~ A kit, comprising: containing a  
the compound of the formula (I) or ~~a~~ the pharmaceutically acceptable  
salt thereof ~~as defined in~~ according to claim 1, and a chemotherapeutic  
agent, as a combination for the simultaneous, separate or successive  
administration in the therapy of a disease in which down-regulation or  
inhibition of the expression or function of the IGF-1 receptor is beneficial.

22. (CURRENTLY AMENDED) ~~Use of a compound of the formula (I) or a~~  
~~pharmaceutically acceptable salt thereof as defined in claim 1, as a~~  
~~pharmacological tool in the development and standardization of in vitro and~~  
~~in vivo test systems for the evaluation of~~ A method of evaluating the effects of  
~~inhibitors of cell cycle activity in laboratory animals~~ interfering with cell  
division by blocking cells in prophase of the mitotic cycle, comprising  
utilizing the compound according to claim 1 as a pharmacological tool in the  
development and standardization of in vitro and in vivo test systems for the  
cells.

\* \* \* \* \*

END OF CLAIM LISTING